🟢 Eupraxia Pharmaceuticals is trading 7.1% up in after-hours trading with no confirmed catalyst

Eupraxia Pharmaceuticals is trading at $7.99, up 7.10%, with no specific after-hours catalyst established.

• On October 9, Eupraxia Pharmaceuticals announced that three abstracts on its EP-104GI RESOLVE trial were accepted for upcoming gastroenterology conferences; the announcement did not link this news to the share-price move.
• U.S. markets also gained during the session: the S&P 500 rose 0.61% and the Dow rose 0.94%; broader sentiment may have contributed. Trading volume was unavailable.